|
|
||||||||
Evidence-Based Laboratory Medicine and Test Utilization |
1 Department of Biostatistics, Université Paris-Descartes, Faculté de Medecine, Hôpital Cochin, Paris, France.
2 Heart Failure Therapeutic Unit, Centre Hospitalier René Dubos, Cergy-Pontoise, France.
3 Department of Internal Medicine, Université Paris-Descartes, Faculté de Médecine, Hôpital Européen Georges Pompidou, Paris, France.
aAddress correspondence to this author at: Département de Biostatistique, Pavillon Saint-Jacques, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75674 Paris Cedex 14, France. Fax 33-1-58-41-19-61; e-mail coste{at}cochin.univ-paris5.fr
Background: Most quantitative diagnostic tests do not perfectly differentiate between persons with and without a given disease. We present a simple method to construct a 3-zone partition for quantitative tests results, including positive and negative zones and a gray zone between, and we describe its use in the diagnosis of heart failure by brain natriuretic peptide (BNP) measurement in acute dyspneic patients.
Methods: We conducted a prospective cohort study of 699 consecutive patients with acute dyspnea who were treated at the emergency department of 3 participating hospitals. Heart failure (acute or decompensated) was assessed independently at discharge by cardiologists blind to the results of BNP measurements.
Results: The discriminatory performance of BNP was insufficient to provide a single cutoff value that could be used to correctly diagnose heart failure in clinical practice. Also, the discriminatory performance differed between patients with and without a history of chronic heart failure. The gray zone of inconclusive results was 167472 ng/L for those without and 0334 ng/L for those with such a history. Diagnosis of the current episode of heart failure by BNP results and history of heart failure was not enhanced by data from any other sources, including electrocardiography.
Conclusions: The gray zone approach applied to the diagnosis of heart failure by BNP might allow sensible cutoff values to be determined for clinical practice according to relevant subgroups of patients. The gray zone approach might be usefully applied to many other quantitative tests and clinical diagnostic or screening problems.
The following articles in journals at HighWire Press have cited this article:
![]() |
P. Ray, S. Delerme, P. Jourdain, and C. Chenevier-Gobeaux Differential diagnosis of acute dyspnea: the value of B natriuretic peptides in the emergency department QJM, July 29, 2008; (2008) hcn080v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure Circulation, July 31, 2007; 116(5): e99 - e109. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |